AXSM
Axsome Therapeutics Inc
179.30$
-1.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -2.1% | -7.2% | +0.5% | +2.4% | +1.3% | +5.0% | +7.2% | +4.6% | +3.1% | +3.5% | +6.7% | |
| – | -1.5% | -8.7% | +0.6% | +3.5% | +1.2% | +2.0% | +8.5% | +5.4% | +4.2% | +3.8% | +7.4% | |
| – | -7.3% | -14.2% | -4.8% | +3.7% | -3.7% | -4.6% | +0.7% | +7.3% | -0.7% | -5.5% | +4.8% | |
| – | -7.3% | -14.2% | -4.8% | +3.7% | -3.7% | -4.6% | +0.7% | +7.3% | -0.7% | -5.5% | +4.8% | |
| – | +20.9% | +7.0% | +18.6% | +3.1% | +14.4% | +13.7% | +23.2% | -1.2% | +14.2% | +11.8% | +10.5% | |
| – | +51.6% | +3.0% | -2.3% | -6.3% | +10.3% | +3.7% | +13.0% | +28.9% | +17.5% | +12.8% | +20.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -2.9% | -3.0% | -3.1% | -3.2% | -3.3% | -3.4% | -3.5% | -3.7% | -3.8% | -3.9% | -4.1% | |
| – | +19.9% | +1.1% | +10.9% | +5.2% | +9.2% | +6.3% | +4.3% | +5.1% | +1.0% | +9.6% | +2.9% | |
| – | +21.1% | +3.7% | +29.5% | +5.2% | +17.3% | +6.0% | +40.3% | +5.3% | +5.1% | +15.9% | +4.8% | |
| – | +189.3% | +40.9% | +46.6% | +11.1% | +12.0% | -30.3% | +3,087.3% | +1.2% | -0.3% | +1.2% | -4.3% | |
| – | +39.8% | +32.2% | +14.0% | +4.7% | +12.1% | +19.0% | +7.0% | -40.8% | +20.9% | +62.8% | -26.0% | |
| – | +0.4% | +0.3% | +0.4% | +0.4% | +0.4% | +0.4% | -35.2% | +0.1% | +0.1% | +0.1% | +0.1% | |
| – | -29.1% | -24.6% | -28.6% | -9.7% | -38.6% | -6.7% | +37.3% | +0.9% | +19.8% | -38.2% | +52.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.5% | +0.1% | +0.4% | +1.2% | +0.8% | +0.7% | +1.2% | +1.2% | +1.2% | +1.1% | +0.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.